Over the next decade, China will rise to be the second largest biopharmaceutical market in the world. Driven by surging income levels and an aging population, increased healthcare spending will translate into huge growth potential in China for biopharma companies. However, opportunity also breeds challenges – from intense competition to price-controlled generics dominating consumer preference. China also follows the “one country, many markets” model, with regional authorities enacting different cost-containment methods. This requires an integrated approach to market entry.

Whether you’re a Chinese company seeking to tap into domestic and global markets, or a multinational company expanding its presence in China, you need a strategic partner to help navigate the many complexities. Combining local expertise with our global resources, Quintiles can help you cost effectively bring your drugs and devices to market faster and demonstrate their safety and effectiveness to drive market adoption.